© 2026 MJH Life Sciences™ and The Center For Biosimilars. All rights reserved. https://www.centerforbiosimilars.com/news The Center For Biosimilars articles The Center For Biosimilars articles en-us Mon, 17 Aug 2026 04:49:14 +0000 5 144 47 https://www.centerforbiosimilars.com/news https://www.centerforbiosimilars.com/Biosimilars_logo.png https://www.centerforbiosimilars.com/view/rituximab-biosimilars-show-comparable-6-month-outcomes-in-aav The Center For Biosimilars Articles us Fri, 14 Aug 2026 18:26:18 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/rituximab-biosimilars-show-comparable-6-month-outcomes-in-aav https://www.centerforbiosimilars.com/view/adalimumab-biosimilar-sustains-efficacy-after-switch-in-saudi-cohort The Center For Biosimilars Articles us Tue, 11 Aug 2026 13:00:00 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/adalimumab-biosimilar-sustains-efficacy-after-switch-in-saudi-cohort https://www.centerforbiosimilars.com/view/analytical-characterization-supports-confidence-in-monoclonal-antibody-biosimilars The Center For Biosimilars Articles us Thu, 06 Aug 2026 13:00:00 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/analytical-characterization-supports-confidence-in-monoclonal-antibody-biosimilars https://www.centerforbiosimilars.com/view/biosimilar-denosumab-shows-cost-effectiveness-over-bisphosphonates-in-pmo The Center For Biosimilars Articles us Tue, 04 Aug 2026 18:51:24 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/biosimilar-denosumab-shows-cost-effectiveness-over-bisphosphonates-in-pmo https://www.centerforbiosimilars.com/view/biosimilars-round-up-july-2026 The Center For Biosimilars Articles us Tue, 04 Aug 2026 15:56:16 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/biosimilars-round-up-july-2026 https://www.centerforbiosimilars.com/view/denosumab-biosimilar-kn012-matches-reference-drug-in-phase-3-osteoporosis-trial The Center For Biosimilars Articles us Thu, 30 Jul 2026 21:10:13 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/denosumab-biosimilar-kn012-matches-reference-drug-in-phase-3-osteoporosis-trial https://www.centerforbiosimilars.com/view/india-s-anti-vegf-biosimilars-cut-costs-expand-access The Center For Biosimilars Articles us Thu, 30 Jul 2026 20:00:00 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/india-s-anti-vegf-biosimilars-cut-costs-expand-access https://www.centerforbiosimilars.com/view/eculizumab-biosimilar-shows-durable-benefit-in-long-term-ahus The Center For Biosimilars Articles us Wed, 29 Jul 2026 16:46:01 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/eculizumab-biosimilar-shows-durable-benefit-in-long-term-ahus https://www.centerforbiosimilars.com/view/biosimilar-bills-gain-steam-in-congress-but-key-reforms-still-wait The Center For Biosimilars Articles us Thu, 23 Jul 2026 19:39:07 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/biosimilar-bills-gain-steam-in-congress-but-key-reforms-still-wait https://www.centerforbiosimilars.com/view/aflibercept-biosimilar-sb15-shows-real-world-efficacy-across-retinal-diseases The Center For Biosimilars Articles us Wed, 22 Jul 2026 20:14:23 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/aflibercept-biosimilar-sb15-shows-real-world-efficacy-across-retinal-diseases https://www.centerforbiosimilars.com/view/biosimilar-ranibizumab-performs-on-par-with-innovator-drug-across-retinal-diseases The Center For Biosimilars Articles us Tue, 21 Jul 2026 13:40:01 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/biosimilar-ranibizumab-performs-on-par-with-innovator-drug-across-retinal-diseases https://www.centerforbiosimilars.com/view/real-world-natalizumab-biosimilar-switch-reduced-treatment-satisfaction-despite-stable-outcomes The Center For Biosimilars Articles us Mon, 20 Jul 2026 17:30:00 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/real-world-natalizumab-biosimilar-switch-reduced-treatment-satisfaction-despite-stable-outcomes https://www.centerforbiosimilars.com/view/romosozumab-biosimilar-matches-reference-in-functional-testing-despite-disulfide-differences The Center For Biosimilars Articles us Thu, 16 Jul 2026 18:00:00 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/romosozumab-biosimilar-matches-reference-in-functional-testing-despite-disulfide-differences https://www.centerforbiosimilars.com/view/fda-accepts-sandoz-generic-tirzepatide-applications-amid-biosimilar-development-gap The Center For Biosimilars Articles us Mon, 13 Jul 2026 15:21:44 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/fda-accepts-sandoz-generic-tirzepatide-applications-amid-biosimilar-development-gap https://www.centerforbiosimilars.com/view/anti-vegf-biosimilars-match-reference-drug-in-indian-retinal-disease-care The Center For Biosimilars Articles us Thu, 09 Jul 2026 14:44:42 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/anti-vegf-biosimilars-match-reference-drug-in-indian-retinal-disease-care https://www.centerforbiosimilars.com/view/rituximab-biosimilar-reached-75-remission-matched-innovator-in-membranous-nephropathy The Center For Biosimilars Articles us Wed, 08 Jul 2026 15:36:21 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/rituximab-biosimilar-reached-75-remission-matched-innovator-in-membranous-nephropathy https://www.centerforbiosimilars.com/view/biosimilar-abp-654-maintains-efficacy-safety-after-repeated-switching-from-ustekinumab The Center For Biosimilars Articles us Tue, 07 Jul 2026 11:00:00 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/biosimilar-abp-654-maintains-efficacy-safety-after-repeated-switching-from-ustekinumab https://www.centerforbiosimilars.com/view/biosimilar-denosumab-matches-reference-drug-for-bone-density-in-chinese-women The Center For Biosimilars Articles us Mon, 06 Jul 2026 15:27:22 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/biosimilar-denosumab-matches-reference-drug-for-bone-density-in-chinese-women https://www.centerforbiosimilars.com/view/biosimilar-makers-push-forward-on-regulatory-and-commercial-fronts The Center For Biosimilars Articles us Thu, 02 Jul 2026 19:07:00 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/biosimilar-makers-push-forward-on-regulatory-and-commercial-fronts https://www.centerforbiosimilars.com/view/positioning-biosimilar-ustekinumab-early-reduces-burden-on-spain-s-national-health-system The Center For Biosimilars Articles us Fri, 26 Jun 2026 14:48:23 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/positioning-biosimilar-ustekinumab-early-reduces-burden-on-spain-s-national-health-system https://www.centerforbiosimilars.com/view/global-biosimilar-rules-diverge-across-who-regions-limiting-patient-access The Center For Biosimilars Articles us Wed, 24 Jun 2026 13:42:34 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/global-biosimilar-rules-diverge-across-who-regions-limiting-patient-access https://www.centerforbiosimilars.com/view/low-biosimilar-awareness-in-ms-patients-points-to-critical-gap-in-nurse-led-education The Center For Biosimilars Articles us Thu, 18 Jun 2026 16:30:00 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/low-biosimilar-awareness-in-ms-patients-points-to-critical-gap-in-nurse-led-education https://www.centerforbiosimilars.com/view/biosimilar-expansion-lower-costs-drive-shift-in-ra-treatment-guidelines The Center For Biosimilars Articles us Thu, 18 Jun 2026 13:00:00 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/biosimilar-expansion-lower-costs-drive-shift-in-ra-treatment-guidelines https://www.centerforbiosimilars.com/view/fda-approves-ranibizumab-hkdz-as-first-interchangeable-available-in-both-vials-and-prefilled-syringes The Center For Biosimilars Articles us Wed, 17 Jun 2026 20:15:51 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/fda-approves-ranibizumab-hkdz-as-first-interchangeable-available-in-both-vials-and-prefilled-syringes https://www.centerforbiosimilars.com/view/biosimilar-switching-maintained-disease-control-in-people-with-ankylosing-spondylitis The Center For Biosimilars Articles us Tue, 16 Jun 2026 19:37:07 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/biosimilar-switching-maintained-disease-control-in-people-with-ankylosing-spondylitis https://www.centerforbiosimilars.com/view/fda-approves-first-biosimilars-interchangeable-with-simponi-simponi-aria The Center For Biosimilars Articles us Wed, 10 Jun 2026 13:00:00 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/fda-approves-first-biosimilars-interchangeable-with-simponi-simponi-aria https://www.centerforbiosimilars.com/view/biosimilar-adoption-and-provider-performance-in-medicare-value-based-payment-models The Center For Biosimilars Articles us Tue, 09 Jun 2026 15:42:27 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/biosimilar-adoption-and-provider-performance-in-medicare-value-based-payment-models https://www.centerforbiosimilars.com/view/fda-approves-immgolis-and-immgolis-intri-as-first-biosimilars-to-golimumab-reference-products-for-ra-and-uc The Center For Biosimilars Articles us Mon, 08 Jun 2026 19:06:59 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/fda-approves-immgolis-and-immgolis-intri-as-first-biosimilars-to-golimumab-reference-products-for-ra-and-uc https://www.centerforbiosimilars.com/view/no-efficacy-loss-after-multiple-ustekinumab-biosimilar-switches-in-psoriasis The Center For Biosimilars Articles us Thu, 02 Apr 2026 16:36:01 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/no-efficacy-loss-after-multiple-ustekinumab-biosimilar-switches-in-psoriasis https://www.centerforbiosimilars.com/view/fda-approves-teva-biosimilar-for-denosumab-in-osteoporosis The Center For Biosimilars Articles us Tue, 31 Mar 2026 14:03:08 +0000 The Center For Biosimilars https://www.centerforbiosimilars.com/view/fda-approves-teva-biosimilar-for-denosumab-in-osteoporosis